• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.重度酒精性肝炎——当前概念、诊断及治疗选择
World J Hepatol. 2014 Oct 27;6(10):688-95. doi: 10.4254/wjh.v6.i10.688.
2
[Diagnostic and therapeutic strategies for severe alcoholic hepatitis].[重症酒精性肝炎的诊断与治疗策略]
Korean J Gastroenterol. 2015 Jan;65(1):4-11. doi: 10.4166/kjg.2015.65.1.4.
3
A prognostic evaluation and management of alcoholic hepatitis.酒精性肝炎的预后评估与管理
Minerva Med. 2017 Dec;108(6):554-567. doi: 10.23736/S0026-4806.17.05136-9. Epub 2017 Jun 9.
4
Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis.酒精性脂肪性肝炎患者的早期肝活检、肝实质内胆汁淤积和预后。
BMC Gastroenterol. 2011 Oct 28;11:115. doi: 10.1186/1471-230X-11-115.
5
Current Medical Treatment for Alcohol-Associated Liver Disease.酒精性肝病的当前医学治疗方法。
J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1333-1348. doi: 10.1016/j.jceh.2022.02.001. Epub 2022 Feb 12.
6
Update on the management of alcoholic steatohepatitis.酒精性脂肪性肝炎的治疗进展。
J Gastrointestin Liver Dis. 2013 Jun;22(2):189-97.
7
Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32.失代偿性酒精性肝病、脂肪性肝炎且Maddrey判别函数<32的患者的长期预后
J Hepatol. 2020 Apr;72(4):636-642. doi: 10.1016/j.jhep.2019.12.023. Epub 2020 Jan 15.
8
Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.酒精性脂肪性肝炎(ASH)和酒精性肝炎(AH):级联事件、临床方面和药物治疗选择。
Expert Opin Pharmacother. 2018 Jun;19(8):779-793. doi: 10.1080/14656566.2018.1465929. Epub 2018 Apr 30.
9
Clinical Presentation and Gene Expression of Acute Alcohol-Induced Microvesicular Steatosis Mimicking Alcoholic Hepatitis.临床表型和基因表达:急性酒精诱导的微泡性脂肪变性酷似酒精性肝炎。
Hepatol Commun. 2021 Jan 9;5(4):618-628. doi: 10.1002/hep4.1669. eCollection 2021 Apr.
10
Prognosis and treatment of patients with acute alcoholic hepatitis.急性酒精性肝炎患者的预后与治疗
Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):471-86. doi: 10.1586/17474124.2014.903800. Epub 2014 Apr 10.

引用本文的文献

1
Treatment outcomes of chronic liver disease and associated factors among patients treated at hospitals in Bahir Dar city, north-west Ethiopia.埃塞俄比亚西北部巴赫达尔市医院收治的慢性肝病患者的治疗结果及相关因素
BMC Gastroenterol. 2025 Mar 6;25(1):141. doi: 10.1186/s12876-025-03719-z.
2
Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management.急性-on-慢性肝衰竭:病理生理机制与管理
Front Med (Lausanne). 2021 Nov 8;8:752875. doi: 10.3389/fmed.2021.752875. eCollection 2021.
3
Liver regeneration and alcoholic liver disease.肝脏再生与酒精性肝病
Ann Transl Med. 2020 Apr;8(8):567. doi: 10.21037/atm.2020.02.168.
4
Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis.上皮剪接调节蛋白 2 介导的选择性剪接重编程严重酒精性肝炎中的肝细胞。
J Clin Invest. 2020 Apr 1;130(4):2129-2145. doi: 10.1172/JCI132691.
5
Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease.点剪切波弹性成像预测酒精性肝病纤维化严重程度和脂肪性肝炎。
Hepatol Int. 2020 Mar;14(2):270-280. doi: 10.1007/s12072-019-10009-w. Epub 2019 Dec 19.
6
Iron-Overload triggers ADAM-17 mediated inflammation in Severe Alcoholic Hepatitis.铁过载触发严重酒精性肝炎中 ADAM-17 介导的炎症。
Sci Rep. 2018 Jul 6;8(1):10264. doi: 10.1038/s41598-018-28483-x.
7
Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome.重症酒精性肝炎患者的基线尿液代谢表型及其与预后的关系。
Hepatol Commun. 2018 Apr 16;2(6):628-643. doi: 10.1002/hep4.1176. eCollection 2018 Jun.
8
Alcoholic Hepatitis: Lost in Translation.酒精性肝炎:翻译中的困境
J Clin Transl Hepatol. 2018 Mar 28;6(1):89-96. doi: 10.14218/JCTH.2017.00054. Epub 2017 Dec 17.
9
Gutuo Jiejiu decoction improves survival of patients with severe alcoholic hepatitis: A retrospective cohort study.固本解酒汤改善重症酒精性肝炎患者生存率:一项回顾性队列研究。
World J Gastroenterol. 2017 Apr 28;23(16):2957-2963. doi: 10.3748/wjg.v23.i16.2957.
10
Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.多能间充质基质细胞:治疗酒精性肝病的一种有前景的策略。
World J Gastroenterol. 2016 Jan 7;22(1):24-36. doi: 10.3748/wjg.v22.i1.24.

本文引用的文献

1
Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.胆红素水平的自发变化可预测酒精性肝炎患者的肝脏相关死亡率。
PLoS One. 2014 Jul 11;9(7):e100870. doi: 10.1371/journal.pone.0100870. eCollection 2014.
2
Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study.粒细胞集落刺激因子治疗重症酒精性肝炎:一项随机初步研究。
Am J Gastroenterol. 2014 Sep;109(9):1417-23. doi: 10.1038/ajg.2014.154. Epub 2014 Jun 17.
3
Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial.己酮可可碱与皮质类固醇治疗重症酒精性肝炎:一项随机、非劣效性、开放试验。
J Hepatol. 2014 Oct;61(4):792-8. doi: 10.1016/j.jhep.2014.05.014. Epub 2014 May 15.
4
Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using an in vitro measure of steroid sensitivity.使用类固醇敏感性的体外测量方法可以可靠地确定重症酒精性肝炎患者的长期预后。
Hepatology. 2015 Mar;61(3):1099. doi: 10.1002/hep.27211. Epub 2014 Jul 31.
5
Current treatment options for alcohol-related liver disease.酒精相关性肝病的治疗选择。
Curr Opin Gastroenterol. 2014 May;30(3):238-44. doi: 10.1097/MOG.0000000000000065.
6
A histologic scoring system for prognosis of patients with alcoholic hepatitis.酒精性肝炎患者预后的组织学评分系统。
Gastroenterology. 2014 May;146(5):1231-9.e1-6. doi: 10.1053/j.gastro.2014.01.018. Epub 2014 Jan 15.
7
Is liver biopsy necessary in the management of alcoholic hepatitis?酒精性肝炎的治疗中是否需要进行肝活检?
World J Gastroenterol. 2013 Nov 28;19(44):7825-9. doi: 10.3748/wjg.v19.i44.7825.
8
Interleukin-1β in innate inflammation, autophagy and immunity.白细胞介素-1β 在先天炎症、自噬和免疫中的作用。
Semin Immunol. 2013 Dec 15;25(6):416-24. doi: 10.1016/j.smim.2013.10.018. Epub 2013 Nov 22.
9
Treating inflammation by blocking interleukin-1 in humans.通过阻断白细胞介素-1 治疗人类炎症。
Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23.
10
Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice.泼尼松龙治疗对小鼠 T/NKT 细胞和肝毒素介导性肝炎的相反作用。
Hepatology. 2014 Mar;59(3):1094-106. doi: 10.1002/hep.26748. Epub 2014 Jan 21.

重度酒精性肝炎——当前概念、诊断及治疗选择

Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.

作者信息

Kim Won, Kim Dong Joon

机构信息

Won Kim, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 156-707, South Korea.

出版信息

World J Hepatol. 2014 Oct 27;6(10):688-95. doi: 10.4254/wjh.v6.i10.688.

DOI:10.4254/wjh.v6.i10.688
PMID:25349640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4209414/
Abstract

Alcoholic hepatitis (AH) is an acute hepatic manifestation occurring from heavy alcohol ingestion. Alcoholic steatohepatitis (ASH) is histologically characterized by steatosis, inflammation, and fibrosis in the liver. Despite the wide range of severity at presentation, those with severe ASH (Maddrey's discriminant function ≥ 32) typically present with fever, jaundice, and abdominal tenderness. Alcohol abstinence is the cornerstone of therapy for AH and, in the milder forms, is sufficient for clinical recovery. Severe ASH may progress to multi-organ failure including acute kidney injury and infection. Thus, infection and renal failure have a major impact on survival and should be closely monitored in patients with severe ASH. Patients with severe ASH have a reported short-term mortality of up to 40%-50%. Severe ASH at risk of early death should be identified by one of the available prognostic scoring systems before considering specific therapies. Corticosteroids are the mainstay of treatment for severe ASH. When corticosteroids are contraindicated, pentoxifylline may be alternatively used. Responsiveness to steroids should be assessed at day 7 and stopping rules based on Lille score should come into action. Strategically, future studies for patients with severe ASH should focus on suppressing inflammation based on cytokine profiles, balancing hepatocellular death and regeneration, limiting activation of the innate immune response, and maintaining gut mucosal integrity.

摘要

酒精性肝炎(AH)是大量饮酒引起的一种急性肝脏表现。酒精性脂肪性肝炎(ASH)在组织学上的特征是肝脏出现脂肪变性、炎症和纤维化。尽管发病时严重程度范围广泛,但重度ASH患者(Maddrey判别函数≥32)通常表现为发热、黄疸和腹部压痛。戒酒是AH治疗的基石,对于较轻形式的AH,戒酒足以实现临床康复。重度ASH可能进展为多器官功能衰竭,包括急性肾损伤和感染。因此,感染和肾衰竭对生存率有重大影响,应对重度ASH患者进行密切监测。据报道,重度ASH患者的短期死亡率高达40%-50%。在考虑特定治疗之前,应通过现有的预后评分系统之一识别有早期死亡风险的重度ASH患者。皮质类固醇是重度ASH治疗的主要药物。当皮质类固醇禁忌时,可改用己酮可可碱。应在第7天评估对类固醇的反应性,并应根据里尔评分启动停药规则。从战略上讲,未来针对重度ASH患者的研究应侧重于根据细胞因子谱抑制炎症、平衡肝细胞死亡和再生、限制固有免疫反应的激活以及维持肠道黏膜完整性。